
Embecta Faces Securities Lawsuit Over Insulin Needle Business Claims
A class action lawsuit filed in the U.S. District Court for the District of New Jersey alleges Embecta Corp. misled shareholders regarding the stability of its insulin pen needle business. Investors who suffered losses between November 25, 2025, and May 4, 2026, now face an August 17 deadline to seek lead plaintiff status.

























